Primary outcomes:
The applied ASP interventions in March 2018 was associated with a significant decrease in carbapenem consumption as indicated by a shift of the mean DDD from 38.9 ± 12.8 DDD /1000 patient-days during the pre-intervention period to 26.6 ± 9.98 DDD / 1000 patient-days in the post-intervention period with 31.6 % decrease by the implementation of the intervention (Figure 1). This change in the carbapenem use was seen to be statistically significant, P = 0.02.